Objective To evaluate the efficiency of low-dose computed tomography (LDCT) screening for
lung cancer in China by analyzing the baseline results of a community-based screening …

In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to
be the leading cause of cancer-related death. The epidermal growth factor receptor is an …

Background Amide proton transfer weighted imaging (APTw), intravoxel incoherent motion
(IVIM), and positron emission tomography (PET) imaging all have the potential to …

Objectives Lung squamous cell carcinoma (LSCC) exhibits poor response to treatment
compared with other lung cancer subtypes, resulting in worse prognosis. Therefore, new …

Background In clinical practice, a number of delayed diagnoses of localized pneumonic-type
lung adenocarcinoma (L-PLADC) mimicking pneumonia have been identified due to the …

Aims Previous studies suggested a significant relationship between four surrogate indexes
of insulin resistance and subsequent type 2 diabetes mellitus (T2DM). But the association of …

Background. Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new
standard treatment for unresectable stage III non-small cell lung cancer. Survival data for …

The tumor immune composition influences prognosis and treatment sensitivity in lung
cancer. The presence of effective adaptive immune responses is associated with increased …

Background Accurate evaluation of programmed death-ligand 1 (PD-L1) expression levels
in cancer patients may be useful in the identification of potential candidates for anti …

Lung squamous cell carcinoma (LUSC) remains a difficult-to-treat disease with a poor
prognosis. While prominin-1 (PROM1/CD-133) is largely investigated in a variety of …